Health Policy

Ivermectin Prophylaxis Used for COVID-19 Reduces COVID-19 Infection and Mortality Rates: A City-Wide, Prospective Observational Study of 220,517 Subjects Using Propensity Score Matching

December, 2021


Background: Ivermectin has demonstrated different mechanisms of action that potentially protect from both COVID-19 infection and COVID-19-related comorbidities. Based on the studies suggesting efficacy in prophylaxis combined with the known safety profile of ivermectin, a citywide prevention program using ivermectin for COVID-19 was implemented in Itajai, a Southern city in Brazil in the state of Santa Catarina. The objective of this study was to evaluate the impact of regular ivermectin use on subsequent COVID-19 infection and mortality rates.

How bad data quality can turn a simulation into a dissimulation that shapes the future

DSA ADS Course, 2022

Data Quality, Black Box Models, Bad Models, Origins of SARS-CoV-2, Epidemiology, Non-pharmaceutical Interventions, Mitigation Strategies, COVID19, Health Policy, Public Policy

Review data quality evaluations, bad model design, policy decision-making based on data science, black box models, unwarranted assumptions in models, and evidence based policy making with near real-time data.

Inhaled Corticosteroids for Outpatients with Covid-19: A Meta-Analysis

November, 2021


The role of inhaled corticosteroids for outpatient COVID-19 is evolving. We meta-analyzed reported clinical trials and estimated probability of any effect and number needed to treat of 50 or 20 for symptom resolution by day 14 [100%, 99.8%, 93.1%] and hospitalization [88.6%, 72.7%, 26.3%] respectively.

Inhaled corticosteroids are widely available, inexpensive in most jurisdictions, have few reported severe side effects and are likely beneficial based on the total evidence to date.